{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030771","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.924616+00:00","generated_at":"2026-05-31T10:58:26.962017+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oncocyte reports Q2 revenue $104K, loss $0.36/sh; launches GraftAssure at two centers","bullets":["Revenue of $104K from pharma services; operating expenses $4.7M; loss from ops $4.5M ($0.36/sh).","GraftAssure RUO assay used at two transplant centers in U.S. and Southeast Asia in July 2024.","Sales funnel represents centers covering ~25% of annual U.S. transplant volumes (11,000+ transplants).","Appointed Andrea James as CFO; she previously led IR at Axon and helped raise >$550M in equity.","Cash & equivalents $11.0M at June 30, up $3.7M sequentially; includes $1.7M restricted cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030771","json":"https://secwatch.observer/filing/0001493152-24-030771.json","markdown":"https://secwatch.observer/filing/0001493152-24-030771.md","text":"https://secwatch.observer/filing/0001493152-24-030771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224030771/0001493152-24-030771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224030771/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:58:26.962017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}